Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1767121rdf:typepubmed:Citationlld:pubmed
pubmed-article:1767121lifeskim:mentionsumls-concept:C0043092lld:lifeskim
pubmed-article:1767121lifeskim:mentionsumls-concept:C0392360lld:lifeskim
pubmed-article:1767121lifeskim:mentionsumls-concept:C1522577lld:lifeskim
pubmed-article:1767121lifeskim:mentionsumls-concept:C0302350lld:lifeskim
pubmed-article:1767121lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:1767121lifeskim:mentionsumls-concept:C0750729lld:lifeskim
pubmed-article:1767121pubmed:issue5lld:pubmed
pubmed-article:1767121pubmed:dateCreated1992-2-18lld:pubmed
pubmed-article:1767121pubmed:abstractTextFive cases of Wegener's granulomatosis treated with cyclophosphamide (CPM) and prednisolone are reported. Four of these patients received intermittent intravenous boluses of cyclophosphamide with the aim of improving the prognosis and renal function and at the same time to attenuate any haematological or vesical toxicity of CPM. The initial response to treatment by boluses of CPM was favourable in all cases but three patients presented with relapses, which were sometimes repeated and boluses of CPM did not enable a remission to be maintained at the time. Recourse to continuous oral therapy in place of bolus therapy proved viable for the maintenance of remission in two cases. The bladder and haematological tolerance to the bolus was satisfactory but an episode of severe neutropenia led to an adaptation of the dose of CPM. The intermittent administration above all the low cumulative dose of CPM obtained with the boluses will explain the better vesical and haematological tolerance observed depending on the capacity to maintain a prolonged remission. The indications for boluses of CPM in the treatment of Wegener's granulomatosis remain uncertain and do not seem to be totally without inconvenience.lld:pubmed
pubmed-article:1767121pubmed:languagefrelld:pubmed
pubmed-article:1767121pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1767121pubmed:citationSubsetIMlld:pubmed
pubmed-article:1767121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1767121pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1767121pubmed:statusMEDLINElld:pubmed
pubmed-article:1767121pubmed:issn0761-8425lld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:RochemaureJJlld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:UrbanTTlld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:CapronFFlld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:LebeauBBlld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:AllaraMMlld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:PrudentJJlld:pubmed
pubmed-article:1767121pubmed:authorpubmed-author:BréchotJ MJMlld:pubmed
pubmed-article:1767121pubmed:issnTypePrintlld:pubmed
pubmed-article:1767121pubmed:volume8lld:pubmed
pubmed-article:1767121pubmed:ownerNLMlld:pubmed
pubmed-article:1767121pubmed:authorsCompleteYlld:pubmed
pubmed-article:1767121pubmed:pagination487-92lld:pubmed
pubmed-article:1767121pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:meshHeadingpubmed-meshheading:1767121-...lld:pubmed
pubmed-article:1767121pubmed:year1991lld:pubmed
pubmed-article:1767121pubmed:articleTitle[Wegener's granulomatosis. Therapeutic indications and follow-up course. Apropos of 5 cases].lld:pubmed
pubmed-article:1767121pubmed:affiliationService de Pneumologie, Hôpital Saint-Antoine.lld:pubmed
pubmed-article:1767121pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1767121pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:1767121pubmed:publicationTypeCase Reportslld:pubmed